• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.

作者信息

Ferrero Dario, Cerrano Marco, Crisà Elena, Aguzzi Chiara, Giai Valentina, Boccadoro Mario

机构信息

Haematology Division, Università degli Studi di Torino, Turin, Italy.

出版信息

Br J Haematol. 2017 Feb;176(4):669-671. doi: 10.1111/bjh.13983. Epub 2016 Feb 23.

DOI:10.1111/bjh.13983
PMID:26914729
Abstract
摘要

相似文献

1
How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.有多少慢性髓系白血病患者能够从诊断进展至深度分子反应并长期停用伊马替尼？一项真实病例经验。
Br J Haematol. 2017 Feb;176(4):669-671. doi: 10.1111/bjh.13983. Epub 2016 Feb 23.
2
Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.一名慢性髓性白血病分子缓解期患者在伊马替尼治疗期间出现del(20q)，停用伊马替尼后其减少。
Leuk Lymphoma. 2016;57(1):201-2. doi: 10.3109/10428194.2015.1037763. Epub 2015 May 12.
3
Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.甲磺酸伊马替尼停药后慢性髓性白血病患者微小残留病检测不到的长期预后
Acta Haematol. 2016;135(3):133-9. doi: 10.1159/000440936. Epub 2015 Nov 5.
4
miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.miR-505-5p和miR-193b-3p：慢性髓性白血病患者伊马替尼反应的潜在生物标志物。
Leuk Lymphoma. 2017 Aug;58(8):1981-1984. doi: 10.1080/10428194.2016.1272681. Epub 2017 Jan 16.
5
Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.伊马替尼——2015年用于慢性髓性白血病一线治疗的新型酪氨酸激酶抑制剂。
JAMA Oncol. 2015 May;1(2):143-4. doi: 10.1001/jamaoncol.2015.50.
6
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.伊马替尼撤药综合征及更长的伊马替尼治疗持续时间与停药后较低的分子复发密切相关：KID研究
Haematologica. 2016 Jun;101(6):717-23. doi: 10.3324/haematol.2015.139899. Epub 2016 Feb 17.
7
Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.通用型伊马替尼治疗慢性髓性白血病：拉脱维亚的两年经验。
Exp Oncol. 2017 Jul;39(2):151-154.
8
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.伊马替尼一线治疗慢性髓性白血病患者的长期疗效。
Leukemia. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152. Epub 2015 Jun 19.
9
The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.根据欧洲白血病网 2013 年的建议，伊马替尼治疗期间出现分子预警反应的慢性髓性白血病患者的结局。
Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e377-e384. doi: 10.1016/j.clml.2019.03.028. Epub 2019 Apr 4.
10
Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.成功管理接受标准剂量伊马替尼治疗的慢性髓性白血病孕妇。
In Vivo. 2019 Sep-Oct;33(5):1593-1598. doi: 10.21873/invivo.11641.

引用本文的文献

1
Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.真实世界中慢性期慢性髓性白血病的治疗反应和酪氨酸激酶抑制剂停药：来自法国观察站的数据。
Ann Hematol. 2022 Oct;101(10):2241-2255. doi: 10.1007/s00277-022-04955-z. Epub 2022 Aug 30.
2
Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients.初诊慢性期慢性髓性白血病患者的深度分子反应和无治疗缓解发生率。
Cancers (Basel). 2020 Sep 4;12(9):2521. doi: 10.3390/cancers12092521.
3
Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs.
慢性髓性白血病的无治疗缓解：患者视角和未满足需求领域。
Leukemia. 2020 Aug;34(8):2102-2112. doi: 10.1038/s41375-020-0867-0. Epub 2020 May 26.
4
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.观察性研究：意大利临床实践中停止使用酪氨酸激酶抑制剂的慢性髓性白血病患者。
Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.
5
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.在临床实践中慢性髓性白血病治疗中断的可行性：来自 236 例全国性系列研究的结果。
Blood Cancer J. 2018 Dec 2;8(10):91. doi: 10.1038/s41408-018-0125-0.
6
Treatment-free remission in patients with chronic myeloid leukemia.慢性髓性白血病患者的无治疗缓解
Int J Hematol. 2018 Oct;108(4):355-364. doi: 10.1007/s12185-017-2295-0. Epub 2017 Jul 8.